The drug candidate that can enhance the effect of chemotherapy
Anna Hultin
Chief office officer
Quisque lacinia magna quis enim ornare eleifend. Ut porttitor sodales nulla non feugiat. Phasellus volutpat, nunc tincidunt molestie rhoncus, mi ipsum tempor elit, nec tempor ipsum augue eu ex. Integer euismod aliquam hendrerit. Sed id sem vestibulum, sollicitudin sapien ut, tristique nulla. Maecenas quis volutpat nunc, a bibendum erat. Integer et turpis risus. Vestibulum viverra, purus sit amet hendrerit hendrerit, lorem dui bibendum lacus, non pellentesque ipsum neque pharetra justo. Aenean a aliquam tellus, in posuere ante. Integer viverra congue urna a sollicitudin.
Holidings:
245 100 shares
171 444 Warrants serie TO1
171 444 Warrants serie TO2
Performance-based share rights 2025-2028
E-mail:
anna.hultin@isofolmedical.com
*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of July 31, 2025.
En rubrik
Quisque lacinia magna quis enim ornare eleifend. Ut porttitor sodales nulla non feugiat.
Govurnace repoart
Govurnace repoart
Govurnace repoart
Upcoming Events
- January 21, 2026 - January 21, 2026
Redeye Fight Cancer Day, Stockholm
Isofol attending during this day with a short presentation followed by a live Q&A session with Redeye’s analysts. - February 18, 2026 - February 18, 2026
Year-end report 2025 - March 10, 2026 - March 11, 2026
Stora Aktiedagarna
Isofol is participating in the Aktiespararna's event on March 10 in Stockholm and will present the company at 1:30 p.m.
| kolumn rubrik 1 | kolumn rubrik 2 | kolumn rubrik 3 | kolumn rubrik 4 |
|---|---|---|---|
| afasdf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf |
| sfasdf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf |
| asfsadf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf |
Last updated: